TNGX - Tango Therapeutics GAAP EPS of -$0.25 in-line revenue of $5.72M misses by $1.01M March, 28 2022 08:16 AM Tango Therapeutics Inc. Tango Therapeutics press release (NASDAQ:TNGX): Q4 GAAP EPS of -$0.25 in-line. Revenue of $5.72M (-37.4% Y/Y) misses by $1.01M. For further details see: Tango Therapeutics GAAP EPS of -$0.25 in-line, revenue of $5.72M misses by $1.01M